Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-03-09
2009-12-15
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C424S130100
Reexamination Certificate
active
07632923
ABSTRACT:
A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 5591829 (1997-01-01), Matsushita
patent: 5695928 (1997-12-01), Stewart
patent: 5952471 (1999-09-01), Griffiths
patent: 6054297 (2000-04-01), Carter et al.
patent: 6291160 (2001-09-01), Lerner et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6416738 (2002-07-01), Theodore et al.
patent: 6992176 (2006-01-01), Reiter et al.
patent: 2003/0129191 (2003-07-01), Theodore et al.
patent: 2003/0165993 (2003-09-01), Buechler et al.
patent: 2003/0223994 (2003-12-01), Hoogenboom et al.
patent: 2005/0250833 (2005-11-01), Attali et al.
patent: 2005/0255101 (2005-11-01), Reiter et al.
patent: 2005/0287141 (2005-12-01), Reiter
patent: 2006/0083735 (2006-04-01), Reiter et al.
patent: 2007/0196369 (2007-08-01), Hoogenboom et al.
patent: 1178116 (2002-02-01), None
patent: 11-510375 (1999-09-01), None
patent: WO 91/12332 (1991-08-01), None
patent: WO 95/29193 (1995-11-01), None
patent: WO 97/02342 (1997-01-01), None
patent: WO 01/72768 (2001-10-01), None
patent: WO 01/96401 (2001-12-01), None
patent: WO 03/068201 (2003-08-01), None
patent: WO 03/070752 (2003-08-01), None
patent: WO 2004/084798 (2004-07-01), None
Daugherty et al., Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a muring monoclonal antibody directed against . . . , Nucleic Acids Research, vol. 19 No. 9, pp. 2471-2476 (May 1991).
GenPept ABG38407 “immunoglobulin light chain variable region [Homo sapiens],” Jul. 2006.
GenPept AAO45455 “immunoglobulin kappa chain variable region [Homo sapiens],” Nov. 2003.
Kondo et al., “Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain,” Journal of Biolological Chemistry, vol. 263 No. 19, pp. 9470-9475 (Jul. 1988).
Poljak et al., Structure and specificity of antibody molecules, Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 272, pp. 43-51 (Nov. 1975).
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity, Proceedings of the National Academy of Sciences, USA, vol. 79, pp. 1979-1983 (Mar. 1982).
Shiono et al., “Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor,” International Immunology, vol. 15 No. 8, pp. 903-913 (Aug. 2003).
Shriner et al., “Comparison of the human immune response to conjugate and polysaccharide pneumococcal vaccination using a reconstituted SCID mouse model,” Vaccine, vol. 24 No. 49-50, pp. 7197-7203 (Nov. 2006).
Reiter et al. “Peptide-Specific Killing of Antigen-Presenting Cells by A Recombinant Antibody-Toxin Fusion Protein Targeted to Major Histocompatibility Complex/Peptide Class I Complexes With T Cell Receptor-Like Specifity”, Proc. Natl. Acad. Sci. USA, 94(9): 4631-4636, 1997.
Andersen et al. “A Recombinant Antibody With the Antigen-Specific, Major Histocompatibility Complex-Restricted Specifity of T Cells”, Proceedings of the National Academy of Sciences, 93(5): 1820-1824, 1996.
Rudikoff et al. “Single Amino Acid Substitution Altering Antigen-Binding Specifity”, Proceedings of the National Academy of Sciences, USA, 79(6):1979-1983, 1982.
Stedman Definition “Fab Fragment”, Stedman's Online Medical Dictionary, 27th Edition. Www.stedmans.com. No Date Available.
??? Definition “Fab”, The Online Medical Ddictionary, cancerweb.ncl.ac.uk/omd/.
Engberg et al. “Recombinent Antibodies With the Antigen-Specific, MHC Restricted Specifity of T Cells: Novel Reagents for Basic and Clinical Investigations and Immunotherpy”, Immunotechnology, 4(Nos. 3-4): 273-278, 1999.
Saito et al. “In Vivo Selection of T-Cell Receptor Junctional Region Sequences by HLA-A2 Human T-Cell Lymphotropic Virus Type 1 Tax11-19 Peptide Complexes”, Journal of Virology, 75(2): 1065-1071, 2001.
Polakova et al. “Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed With An Antigenic Peptide: Similarities to A T Cell Receptor With the Same Specifity”, The Journal of Immunology, 165: 5703-5712, 2000.
Chung et al. “Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antbody”, The Journal of Immunology, 167: 699-707, 2001.
Robert et al. “Antibody-Conjugated MHC Class I Tetramers Can Target Tumor Cells For Specific Iysis by T Lumphocytes”, European Journal of Immunology, 30: 3165-3170, 2000.
Yoshida et al. “Isolation And Characterization Of Retrovirus From Cell Lines Of Human Adult T-Cell Leukemia And Its Implication In the Disease”, PNAS, 79:2031-2035, 1982.
Köhler et al. “Continuous Cultures Of Fused Cells Secreting Antibody Of Predefined Specificity”, Nature, 256:495-497, 1975.
Harding et al. “Quantitation of Antigen-Presenting Cell MHC Class II/ Peptide Complexes Necessary for T-Cell Stimulation”, Nature, 346: 574-576, 1990.
Christinck et al. “Peptide Binding To Class I MHC On Living Cels And Quantitation of Compplexes Required For CTL Lysis”, Nature, 352: 67-70, 1991.
Aharoni et al. “Immunomodulation Of Experimental Allergic Encephalomyelitis By Antibodies To The Antigen-Ia Complex”, Nature, 351: 147-149, 1991.
Haard et al. “A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rabipd Isolation And Kinetic Analysis Of High Affinity Antibodies”, The Journal of Biological Chemistry, 274(26): 18218-18230, 1999.
Winter et al. “Man-Made Antibodies”, Nature, 349: 293-299, 1991.
Stubbs et al. “Influence Of Core Fucosylation On TheFlexibility Of A Biantennary N-Linked Oligosaccharide”, Bichemistry, 35: 937-947, 1996.
Hoogenboom et al. “By-Passing Immunisation—Human Antibodies From Synthetic Repertoires Of Germline VH Gene Segments Rearranged In Vitro”, Journal of Molecular Biology, 227:381-388, 1992.
Grassmann et al. “Transformation To Continuous Growth Of Primary Human T Lymphocytes By Human T-Cell Leukemia Virus Type I X-Region Genes Tranduced By A Herpesvirus Saimiri Vector”, PNAS, 86: 3351-3355, 1989.
Poiesz et al. “Detection And Isolation Of Type C Retrovirus Particles From Fresh And Cultured Lymphocytes Of A Patient With Cutaneous T-Cell Lymphoma”, PNAS, 77(12): 7415-7419, 1980.
Porter “The Hydrolysis Of Rabbit γ-Globulin And Antibidies With Crystalline Papain”, Biochemical Journal, 73:119-126, 1959.
Pozzatti et al. “The Human T-Lymphotropic Virus Type I “Tax” Gene Can Cooperate With The “Ras” Oncogene To Induce Neoplastic Transformation Of Cells”, Molecular and Cellular Biology, 10(1): 413-417, 1990.
Neuberger “Generating High-Avidity Human Mabs InMice”, Nature Biotechnology, 14, 1996.
Bird et al. “Single-Chain Antigen-Binding Proteins”, Science, 242: 423-426, 1988.
Marks et al. “By-Passing Immunization—Human Antibodies From V-Gene Libraries Displayed On Phage”, Journal ofMelcular Biology, 222: 581-597, 1991.
Cote et al. “Generation Of Human Monoclonal Antibodies Reactive With Cellular Antigens”, PNAS, 80: 2026-2030, 1983.
Riechmann et al. “Reshaping Human Antibodies for Therapy”, Nature 332: 323-327, 1
Cohen Cyril
Reiter Yoram
Lucas Zachariah
Technion Research & Development Foundation Ltd.
LandOfFree
Compositions capable of specifically binding particular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions capable of specifically binding particular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions capable of specifically binding particular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4102725